Richard A. Larson to Biological Availability
This is a "connection" page, showing publications Richard A. Larson has written about Biological Availability.
Connection Strength
0.270
-
PepsiĀ® or CokeĀ®? Influence of acid on dasatinib absorption. J Oncol Pharm Pract. 2018 Mar; 24(2):156-158.
Score: 0.141
-
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012 May; 68(5):723-33.
Score: 0.098
-
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol. 2005 May 20; 23(15):3404-11.
Score: 0.015
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.015